An observational study in Obesity and Overweight, sponsored by Texas Tech University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Texas Tech University · Observational
Among 21 studies in Obesity by Texas Tech University — 3 open to participants now, 4 under way, none of them phase 3. Obesity · Texas Tech University.
Among the 21 studies in Obesity by Texas Tech University, this one is one of 2 that started in 2025, is one of 2 observational ones, and was the 19th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →3 of the 21 studies in Obesity by Texas Tech University are open now, in 1 country. Recruiting first, the newest first:
Texas Tech University · Sites in United States
Ages 11–14
Texas Tech University · Sites in United States
Ages 18+ · Healthy volunteers
Texas Tech University
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is below the median of 114 across 2,154 observational studies indexed under Obesity.
Median enrollment 27 across the 19 interventional studies, 114 across the 2 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
Texas Tech University is the lead sponsor of 82 studies on the registry; 11 are open to participants now.
3 of the studies in Obesity by Texas Tech University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07740291Texas Tech UniversityTirzepatide Impact Assessment Study | 2026-11-23 |
| NCT06755827Texas Tech UniversityPilot Testing a Novel Approach to Pediatric Obesity Treatment | 2026-12-31 |
| NCT07557979Texas Tech UniversityComparison Between the Health Effects of an AI-driven Model With Those of Human Professional Guidelines for the Treatment of Obesity | 2027-03-31 |
Among the 21 studies in Obesity by Texas Tech University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn about the real-world effects of selected obesity medications in adults undergoing medical weight management. The main outcomes of interest are changes in body composition, routine clinical markers, muscular performance, and nutritional intake over the course of treatment. Additionally, the influence of lifestyle factors on changes in these outcome variables will be examined.
Participants beginning treatment with selected obesity medications will undergo periodic body composition and muscular performance testing, as well as complete online surveys about their nutritional intake and physical activity and exercise participation. Additionally, routinely collected clinical information will be evaluated.
Background. The popularity of anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide and dual GLP-1/GIP receptor agonists like tirzepatide, has increased dramatically over the past several years. These medications are routinely prescribed in obesity management clinics and other medical settings. While controlled clinical trials have been conducted for specific drugs, many of these have not reported relevant outcomes, such as body composition changes, muscular performance, and nutritional intake. Additionally, these controlled clinical trials may not fully represent the "real world" effects of treatment in varied settings. As such, there is a need for observational, real-world evaluations of the effects of GLP-1RA and GLP-1/GIP drugs on body composition, muscular performance, nutritional intake, and routine clinical markers. Additionally, the influence of lifestyle factors, such as exercise participation, on the observed changes in these outcomes should be evaluated.
Overview. Eligible participants beginning treatment with selected obesity medications (semaglutide or tirzepatide) at a specified virtual health clinic will undergo periodic body composition and muscular performance testing, as well as complete online surveys about their nutritional intake and physical activity and exercise participation. Additionally, routinely collected clinical information will be evaluated.
Body Composition Assessment. Participants will be asked to report an approved local DXA testing facility for a baseline body composition assessment as close as possible to the beginning of their anti-obesity medication treatment. Participants will be requested to report for another scan after \~6 months of treatment, as well as after \~17 months of treatment (provided they are still undergoing treatment at this point).
Handgrip Strength Testing. Handgrip testing will take place using a standard, consumer-grade at-home handgrip dynamometer, which will be provided to each participant. Participants will be provided with instructions for conducting the handgrip testing. This testing will be completed at baseline (as close as possible to the initiation of anti-obesity medication), and after \~3, \~6, and \~17 months of treatment (provided they are still undergoing treatment at these time points).
Questionnaires. The following questionnaires will be completed at baseline (as close as possible to the initiation of anti-obesity medication), and after \~3, \~6, and \~17 months of treatment (provided they are still undergoing treatment at these time points):
Standard Clinical Markers. Some clinical markers routinely collected during standard medical treatment will also be evaluated, including a lipid panel (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), hemoglobin A1C, glucose, and blood pressure.
Power Analysis. A priori power analyses were conducted for repeated-measures ANOVA (within-subjects factors) using G*Power to determine the required sample size. The analyses used a conservative effect size (f = 0.25; "medium" strength), an alpha error probability (α) of 0.05, a desired statistical power (1-β) of 0.8, and specified one group. Ranges of number of repeated measures (2 to 4), correlations between repeated measures (0.25 to 0.5), and nonsphericity corrections (ε; 0.8 to 1) were implemented. These analyses indicated the total sample size required to achieve adequate power ranged from 24 to 50 participants. A priori power analyses were conducted for linear multiple regression (R2 deviation from zero) using G*Power to determine the required sample size for analyses examining predictors of variation in changes in outcome variables. A medium strength effect size (f2=0.15), an alpha error probability (α) of 0.05, and a desired statistical power (1-β) of 0.8 were specified. This analysis indicated that up to 6 predictors could be included in the regression model at a sample size of 98 participants. Based on consideration of these analyses, a target sample size of 100 was specified.
Statistical Analysis. Comprehensive descriptive data will be presented. Changes in all outcome variables over time will be quantified using appropriate statistical methods (e.g., repeated-measures ANOVA or a similar linear model). Additionally, the potential influence of lifestyle factors - particularly nutritional intake, physical activity level, and participation in muscle-strengthening activities - and medication type (semaglutide vs. tirzepatide) on outcome measures will be explored using an appropriate method (e.g., multiple linear regression or a related linear model, such as a linear mixed-effects model).
The study population is eligible individuals who are undergoing standard obesity medication treatment at a specified virtual obesity medicine practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This cohort will be comprised of individuals who are beginning obesity medication treatment at a specified virtual obesity medicine practice. Patients taking semaglutide or tirzepatide may be eligible for inclusion in this cohort.
This study also gives Semaglutide, Tirzepatide. No intervention listed here names it: that was found by reading the record.
Change in Total Lean Soft Tissue
Change in total lean soft tissue assessed by dual-energy X-ray absorptiometry.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
Change in Appendicular Lean Soft Tissue
Change in appendicular lean soft tissue assessed by dual-energy X-ray absorptiometry.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
Change in Total Fat Mass
Change in total fat mass assessed by dual-energy X-ray absorptiometry.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
Change in Handgrip Strength
Change in maximal handgrip strength as determined by a handgrip dynamometer.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Change in Total Body Mass
Change in total body mass assessed by dual-energy X-ray absorptiometry.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
Change in Total Body Fat Percentage
Change in total body fat percentage assessed by dual-energy X-ray absorptiometry.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
Change in Total Bone Mineral Content
Change in total bone mineral content assessed by dual-energy X-ray absorptiometry.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
Change in Visceral Fat
Change in visceral fat assessed by dual-energy X-ray absorptiometry.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~6 months and ~17 months after baseline).
Change in Total Cholesterol
Change in total cholesterol as assessed by a lipid panel.
Time frame: From baseline assessment to last available time point.
Change in LDL Cholesterol
Change in low-density lipoprotein cholesterol as assessed by a lipid panel.
Time frame: From baseline assessment to last available time point.
Change in HDL Cholesterol
Change in high-density lipoprotein cholesterol as assessed by a lipid panel.
Time frame: From baseline assessment to last available time point.
Change in Triglycerides
Change in triglycerides as assessed by a lipid panel.
Time frame: From baseline assessment to last available time point.
Change in Hemoglobin A1C
Change in hemoglobin A1C as assessed by a routine blood panel.
Time frame: From baseline assessment to last available time point.
Change in Glucose
Change in blood glucose as assessed by a blood panel.
Time frame: From baseline assessment to last available time point.
Change in Blood Pressure
Change in blood pressure as assessed by sphygmomanometry.
Time frame: From baseline assessment to last available time point.
Energy Intake
Total energy intake as assessed by the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Protein Intake
Total protein intake as assessed by the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Carbohydrate Intake
Total carbohydrate intake as assessed by the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Fat Intake
Total fat intake as assessed by the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Fiber Intake
Total fiber intake as assessed by the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Sugar Intake
Total sugar intake as assessed by the Automated Self-Administered 24-hour (ASA24®) Dietary Assessment Tool.
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Muscle-strengthening activity level
Degree of participation in muscle-strengthening activities as assessed by the Muscle-Strengthening Exercise Questionnaire (MSEQ)
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Physical activity level
Physical activity level as assessed by the International Physical Activity Questionnaire (IPAQ)
Time frame: From baseline assessment to last available time point (follow-up assessments conducted ~3, ~6, and ~17 months after baseline).
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Mar 2028, 38 months after the start.
Of 791 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 38 months is close to that.
Counting every sponsor, half of 836 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2027 → Mar 2028 and completion Dec 2027 → Mar 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Texas Tech University